Advertisement
Human Cancer Biology

ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia

Marta Crespo, Neus Villamor, Eva Giné, Ana Muntañola, Dolors Colomer, Teresa Marafioti, Margaret Jones, Mireia Camós, Elias Campo, Emili Montserrat and Francesc Bosch
DOI: 10.1158/1078-0432.CCR-05-1531 Published February 2006

Abstract

Purpose: The ZAP-70 gene is normally expressed in T and natural killer cells, where it is required for the T-cell receptor (TCR) signaling. More recently, it has been described that ZAP-70 contributes to the B-cell development at early stages of B-cell differentiation in mice. The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).

Experimental Design: ZAP-70 expression was ascertained by flow cytometry, immunofluorescence, Western blot, and quantitative reverse transcription-PCR. Analysis of ZAP-70 and other signaling proteins of the pre-TCR/TCR was done by Western blot.

Results: ZAP-70 was expressed in pro/pre B cells but not in normal mature B cells derived from bone marrow, peripheral blood, or tonsil. Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas. In B-ALL cells, expression of CD38 protein correlated with ZAP-70 expression (P = 0.05). Mutational analysis of the ZAP-70 gene revealed the absence of mutations in cases lacking ZAP-70 expression. Moreover, other elements of the pre-TCR/TCR signaling pathway, like LAT and Lck, were also found in B-ALL cells.

Conclusions: Among normal B-cell subsets, ZAP-70 was found expressed in normal pro/pre B cells but not in a significant proportion of normal B cells with mature phenotype. Moreover, the presence of ZAP-70 in B-ALLs probably reflects their cellular origin. The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.

  • ZAP-70
  • pro/pre B cells
  • B-ALL
  • mature B cells
  • Burkitt

ZAP-70 (ξ-associated protein) is a tyrosine kinase of the Syk/ZAP-70 family that plays a critical role in signal transduction from the T-cell receptor (TCR; refs. 1–3). In response to TCR stimulation, the immunoreceptor tyrosine-based activation motifs become phosphorylated, allowing recruitment and phosphorylation of Syk/ZAP-70 tyrosine kinases. Following these steps, TCR-linked signal transduction takes place, including differentiation, proliferation and effector functions of the cell (4, 5).

The ZAP-70 gene has been reported to be expressed in T and natural killer derived cells. However, in recent studies, ZAP-70 expression has also been found in B-chronic lymphocytic leukemia (CLL; ref. 6) cells, particularly in those cases with unmutated IgVH genes (7–9). Of note, CLL cases with increased ZAP-70 expression have a worse prognosis in terms of progression and survival. In CLL cells, ZAP-70 can be phosphorylated and functionally active upon B-cell receptor (BCR) stimulation (10). The activated ZAP-70 can cooperate with Syk, the tyrosine kinase of the BCR signal pathway normally expressed in B cells, thus inducing proliferation of the CLL cells (10). The mechanisms of the abnormal expression of ZAP-70 in CLL cells, a B-cell mature proliferation, are not fully understood. It has been hypothesized that the expression of ZAP-70 was derived from the cell that this leukemia originated from, or that its expression was ectopic in this cell lineage.

No expression of ZAP-70 in other B-cell compartments had been reported until recently, when ZAP-70 expression was shown to play an important role for B-cell development in mice (11). Consistent with this, ZAP-70 expression was found in mice pro-B, pre-B, and CD19+ splenic B cells, although at lower levels than in normal thymocytes. The expression of ZAP-70 in normal human B cells at different stages of differentiation, especially in the mature B-cell compartment, has not yet been fully elucidated. Thus, it is of great interest to know whether expression of ZAP-70 in mature B-cell–derived neoplasms is a consequence of their cellular origin.

To address these questions, ZAP-70 expression was analyzed by different methods in normal human B cells at different stages of B-cell maturation, including normal pro/pre B cells and mature B cells. In addition, expression and mutational status of ZAP-70 was analyzed in B-ALL cells, including Burkitt's cases and B-ALLs with pro/pre B phenotype. The phosphorylation status of ZAP-70 and other signaling proteins was analyzed in these cases.

Materials and Methods

Samples. Normal lymphocytes were isolated on a Ficoll/Hypaque (Seromed, Berlin, Germany) gradient from peripheral blood lymphocytes (PBL; n = 2) and bone marrow (n = 8) obtained from adults and tonsil (n = 4) obtained from children. In addition, tumoral cells from 29 B-ALL cases, classified according to their maturation status (12), were included in this study: status B-I (CD19+, CD10−, cIgM−), four cases; B-II (CD19+, CD10+, cIgM−), 18 cases; B-III (CD19+, CD10+, cIgM+), one case; and B-IV/Burkitt (CD19+, CD10+, sIgM+), six cases (Table 1). Moreover, tumoral lymphocytes obtained from 10 patients diagnosed with CLL were also analyzed for ZAP-70 expression. The cell lines Jurkat (T-ALL), NALM-6 (B-ALL), Ramos, Daudi, Namalwa, Raji (Burkitt), JVM-2 (prolymphocytic leukemia), and NC-NC (lymphoblastoid) were used as controls. The main clinical (age, response to treatment, duration of response, and survival) and biological variables of the cases diagnosed with B-ALL were recorded and correlated with ZAP-70 expression. Samples were obtained after informed consent and approval from the local Ethical Committee.

View this table:
Table 1.

ZAP-70 expression values and main characteristics of the B-ALLs, normal controls, and cell lines

In normal PBLs, CD19+ lymphocytes were negatively selected using the B-cell Isolation kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) followed by a further negative selection using anti-CD56, anti-CD2, and anti-CD3-FITC labeled (Becton Dickinson, San Jose, CA). In normal bone marrow, CD19+/CD10+ lymphocytes were positive selected using anti-CD10-phycoerythrin (PE) followed by anti-CD19-FITC (Becton Dickinson). In tonsils, the subpopulations CD19+/CD27−, CD19+/CD27+, and CD19− were isolated by separation of CD19+ cells with anti-CD19-FITC followed by further purification of CD27+ cells with anti-CD27-PE (Becton Dickinson). In tumoral samples (B-ALLs and CLL cases), isolation of CD19+ cells was done by separation of CD3+ cells with anti-CD3-FITC. Labeled cells were collected correspondingly using anti-FITC, anti-PE, or anti-biotin Microbeads (Miltenyi Biotec). Isolated samples were analyzed for ZAP-70 expression when the presence of T and natural killer cells was <1%.

Flow cytometry analysis of ZAP-70. Flow cytometry analysis of ZAP-70 expression was done as previously described (7). Several surface markers combinations were used to assess ZAP-70 expression on the different cell subsets: (a) for B-cell subsets in normal bone marrow, to analyze simultaneously T cells and different subsets of B cells, ZAP-70-FITC/CD20-PE+CD3−PE/CD19-peridin chlorophyll protein cychrome 5.5 (PerCP Cy5.5)/CD10-allophycocyanine (APC)+CD3-APC or CD34-APC+CD3-APC; (b) for CLL, ZAP-70-FITC/CD3-PE+CD56-PE/CD19-PerCP Cy5.5/CD5-APC; and (c) for B-ALL, ZAP-70-FITC/CD3-PE+CD56-PE/CD19-PerCP Cy5.5/CD10-APC or CD34-APC. ZAP-70 monoclonal antibody was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY), and the surface markers were from Becton Dickinson (CD56-PE, CD19 PerCP Cy5.5, CD5-APC, CD3-APC) and Immunotech (Marseilles, France; CD20-PE, CD10-APC, CD34-APC, CD3-PE). Mean fluorescence channel intensity was obtained for each lymphoid subpopulation, and the ratios between T and pro/pre B cells or mature B cells were compared using the Mann-Whitney test.

Double immunofluorescence analysis of ZAP-70. Five-micrometer-thick paraffin-embedded tissue sections of reactive tonsil, tonsil cell suspensions, or mononucleated cells from peripheral blood were dewaxed and rehydrated when necessary and then submitted to antigen retrieval by heating in 0.01 mol/L Tris-EDTA (pH 9.0) for 2 minutes in a conventional pressure cooker. Double immunofluorescence labeling for ZAP-70 and CD20 was done following the instructions previously described (13, 14).

The staining was examined using an E800 Eclipse fluorescence microscope (Nikon, Kingston-upon-Thames, United Kingdom). Images were captured using an Axiocam CCD camera and Axiovision software (Imaging Associates, Bicester, United Kingdom) and then opened using Adobe Photoshop (Adobe Systems, Inc., San Jose, CA).

Quantitative real-time RT-PCR of ZAP-70. Total RNA was isolated from 20 B-ALL cases (in eight cases from isolated CD19+ cells), purified CD19+/CD27−, CD19+/CD27+, and CD19− tonsil cells, normal PBLs, 10 CLL cases, and from cell lines using the guanidinium thiocyanate method (Ultraspec RNA; Biotecx Laboratories, Houston, TX) according to the manufacturer's instructions. cDNA was synthesized from 1 μg of RNA using 260 units of Moloney murine leukemia virus reverse transcriptase (Invitrogen, Life Technologies, Carlsbad, CA), 26 units of RNAse inhibitor (Promega, Madison, WI), and 4.7 μg of random hexanucleotides (Pharmacia, Uppsala, Sweden).

Quantitative real-time RT-PCR (QRT-PCR) was done with Taqman technology and the ABI PRISM 7700 Sequence Detector System (Applied Biosystems, Foster City, CA). ZAP-70 primers and Taqman probe (FAM labeled at the 5′ end) were used at 300 and 200 nmol/L, respectively. Sequences of primers and the probe can be found at http://www.idibaps.ub.edu/images/noticias/ZAP70SEQ.pdf. The Jurkat T-cell line was used as a positive control for expression of ZAP-70, and GUS (β-glucoronidase) expression was used as endogenous control. The cycle threshold values of each sample were used to analyze the data, as the cycle threshold is inversely proportional to the amount of target cDNA. All samples were analyzed in triplicates. The PCR arbitrary units (AU) were defined as the mRNA levels of ZAP-70 normalized to the GUS expression. RNA from Jurkat T cells was used as reference control to normalize ZAP-70/GUS amplification ratios.

ZAP-70 expression was analyzed by QRT-PCR and flow cytometry in 7 B-ALLs and 10 CLLs. Values obtained by both methods were correlated using a regression test. Finally, to assess the influence in ZAP-70 expression of T cells present in B-ALL samples, serial dilutions of Jurkat and JVM-2 (a cell line that did not express ZAP-70; ref. 7) were done and analyzed by QRT-PCR.

Western blotting. Cryopreserved B-ALL cells were thawed and maintained at 37°C and 5% CO2 in RPMI/10% FCS for 1 hour. Then, cells were washed with RPMI serum-free culture medium and resuspended in 400 μL of RPMI serum-free. For pervadanate treatment, equal volumes of solutions containing 300 mmol/L H2O2 and 100 mmol/L NaVO4 were mixed immediately before use and added to B-ALL cells at a final concentration of 1.5 mmol/L H2O2 and 0.5 mmol/L NaVO4. Cells were incubated for 4 minutes at 37°C, pelleted, and lysed on ice for 30 minutes in lysis buffer containing 20 mmol/L Tris (pH 7.4), 1 mmol/L EDTA, 140 mmol/L NaCl, 1% Triton X-100, 2 mmol/L NaVO4, and 1× proteases inhibitor cocktail (Sigma, St Louis, MO). After centrifugation (5 minutes at 13.2 × 103 rpm), supernatants were collected and used for Western blot analysis.

Isolated populations from normal tonsils, bone marrow, and PBLs were pelleted and lysed on ice for 30 minutes in lysis buffer, and supernatants were collected by centrifugation.

Cell lysates were subjected to electrophoresis in 10% polyacrylamide gels and transferred to Immobilon-phosphate membranes. Membranes were incubated with the following primary antibodies: anti-phosphotyrosine, anti-phospho-ZAP-70 (Tyr319)/phospho-Syk (Tyr352; Cell Signaling Technology, Beverly, MA); anti-ZAP-70, clone 2F3.2; anti-PLCγ2; anti-LAT, anti-phospho-LAT (Tyr226); anti-Lck, clone 3A5; and anti-α-tubulin (all purchased from Upstate). Chemiluminescent images were detected with the LAS-3000 system and analyzed with Image Gauge V4.0 software (Fuji Photo Film Co., Carrollton, TX).

ZAP-70 mutational analysis in B-ALLs. Genomic DNA was isolated from tumoral lymphocytes from four B-ALL patients (two of them with high ZAP-70 expression) using a sodium chloride extraction method (15). The coding region of the ZAP-70 gene (starting at the position −697 bp upstream of the transcription start site and including intronic flanking regions) was amplified by PCR (see http://www.idibaps.ub.edu/images/noticias/ZAP70SEQ.pdf). PCR products were purified and directly sequenced from both strands using the Big Dye Terminator Cycle sequencing V3.1 Ready Reaction. Sequence analysis and alignments were done using the Blast 2 sequences tool (16).

Results

ZAP-70 expression in normal B-cell subsets. ZAP-70 protein was analyzed by flow cytometry in pro/pre B cells (CD19+/CD10+/CD20− or CD19+/CD34+) and in CD19+/CD20+/CD34−/CD10− (mature) B-cell subpopulations from eight normal bone marrows. Among the different B-cell subsets analyzed, expression of ZAP-70 was found to be higher in pro/pre B cells (CD19+/CD10+ or CD19+/CD34+) than in mature B cells (CD19+/CD34−/CD10−; Fig. 1A and B). The analysis of mean fluorescence intensity showed that ZAP-70 ratios between T cells and pro/pre B cells were lower than ratios between T cells and mature B cells (3.72 versus 5.51, respectively; P = 0.002; data not shown). To confirm these results and to exclude the possibility of a nonspecific staining of ZAP-70 in the different B-cell subsets, CD19+/CD10+ cells from bone marrow were isolated and ZAP-70 expression analyzed by Western blotting. With this method, expression of ZAP-70 was confirmed in CD19+/CD10+ purified cells. (Fig. 1C). Unfortunately, analysis of ZAP-70 in the CD19+/CD34+ subset was not done due to the low number of recovered cells.

Fig. 1.
Fig. 1.

ZAP-70 expression in normal B cells from bone marrow. A, analysis of ZAP-70 expression by flow cytometry. A1, gate for selecting T cells (strong positive in both PE and APC). A2, gate for B cells (CD19+). A3, gate for selecting CD10+ and mature CD20+/CD10− B cells. A4, gate for CD34+ B cells. Right, overlapping histograms of ZAP-70 staining in T cells, mature B cells, and CD34+ and CD10+ B cells from a normal bone marrow sample. As shown, normal CD34+ B cells expressed higher levels of ZAP-70 than CD10+ B cells and mature B cells. B, intracellular content of ZAP-70 in different B-cell subsets from bone marrow. The most immature B cells (CD34+) showed the highest content of ZAP-70 amongst B cells subpopulations. MFI, mean fluorescence intensity channel. C, Western blot analysis of ZAP-70 expression in purified CD19+/CD10+ cells from bone marrow. Jurkat and NC-NC protein extracts were used as positive and negative control for ZAP-70, respectively. PLCγ2 (mainly expressed by B cells) and α-tubulin were used as loading controls. Confirming flow cytometry results, CD19+/CD10+ B cells disclosed ZAP-70 expression, although at lower levels than T cells.

ZAP-70 expression was then analyzed in mature B cells derived from normal tonsil. In CD19+/CD27− and CD19+/CD27+ cells from tonsil, levels of ZAP-70 expression obtained by QRT-PCR were as low as the negative controls, whereas in CD19− cells, the expression was similar to PBLs (Table 1). Furthermore, tonsil slides and cell suspension were analyzed using immunofluorescence with anti-ZAP-70 and anti-CD20 double staining. Again, ZAP-70 was found expressed in T-cell areas, whereas no mature B cells in germinal center, mantle zone or marginal zone, were positively stained with ZAP-70 (Fig. 2). In addition, immunoblot analysis done on protein extracts obtained from these subsets did not detect a significant presence of ZAP-70 protein (Fig. 3). Moreover, double staining of tonsil cell suspensions detected only one double-positive cell for CD20 and ZAP-70 among >1,000 cells analyzed (Fig. 3).

Fig. 2.
Fig. 2.

ZAP-70 expression in normal mature B cells from tonsil sections. Double immunofluorescence labeling for ZAP-70 and CD20 on paraffin sections of human tonsil. Top, ZAP-70 (green) labels scattered cells located in germinal centers (GC) and mantle zone (MZ) of secondary follicles (top left). Top middle, anti-CD20 staining (red) shows that the ZAP-70–positive (green) cells seem to be CD20 negative as can be better observed in the merged image (top right). Middle, at higher magnification, the three images (left, middle, and right) further illustrate the absence of ZAP-70/CD20 double-positive cells. Bottom left, in the interfollicular area, T cells express ZAP-70 (green), whereas large interfollicular B cells and small B lymphocytes are CD20+(red; middle and right).

Fig. 3.
Fig. 3.

ZAP-70 expression in cell suspensions from tonsil. A, double immunofluorescence labeling for CD20 (green) and ZAP-70 (red) on cell suspensions from tonsil mononuclear cells showing only one double-positive cell (arrow) among >1,000 cells analyzed. B, Western blot analysis of CD19−, CD19+/CD27−, and CD19+/CD27+ subpopulations from two normal tonsils. ZAP-70 relative expression was expressed as a ratio between ZAP-70 and α-tubulin, being the expression in Jurkat T cells the reference. The percentage of CD19− cells contaminating CD19+ cell lysates is indicated. ZAP-70 protein was only found in CD19− subfractions, whereas CD19+/CD27− and CD19+/CD27+ populations did not show a significant expression of ZAP-70. The faint band observed in CD19+ cells is explained by the T-cell content of the samples, as is reflected in the ratios of expression.

ZAP-70 expression was analyzed in normal PBLs by immunofluorescence and Western blot. Immunofluorescence analysis did not detect cells with double-positive staining of ZAP-70 and CD20. These results were confirmed by Western blot analysis of CD19+ purified cells (Fig. 4).

Fig. 4.
Fig. 4.

ZAP-70 expression in mature B cells from peripheral blood. ZAP-70 expression was analyzed in normal PBLs by immunofluorescence and Western blot. A, immunofluorescence analysis using ZAP-70/CD20 staining did not disclose the presence of double-positive cells. B, immunoblots of CD19+ selected cells did not show ZAP-70 expression, opposite to the intensity of expression observed in Jurkat, PBLs, and selected CD3+ cells.

ZAP-70 expression in B-ALLs. B-ALLs are aggressive neoplasms that derive from B cells with pro/pre B phenotype (B-I, B-II, B-III) or from mature germinal center B cells (B-IV and/or Burkitt/ALL). Because we found ZAP-70 expression in normal CD34+ or CD10+ B cells, the analysis of its expression was then done in a series of 29 B-ALL cases at different status of maturation.

ZAP-70 expression was ascertained by FC in 16 cases, by QRT-PCR in 20 cases, and by both methods in seven cases. The flow cytometry analysis of primary B-ALL cells disclosed a high expression of ZAP-70 in 12 of 16 cases (average expression, 80%; range, 56-99%; Table 1; Fig. 5), whereas in the remaining cases, the expression was considered low (average expression, 7%; range, 1-14%).

Fig. 5.
Fig. 5.

Quantitative analyses of ZAP-70 expression in B-ALLs. A, QRT-PCR analysis of 20 B-ALL cases. Nine cases (black columns) exhibited levels of ZAP-70 mRNA superior to those obtained in normal mature B cells. Bar, 3 SD. B, flow cytometry analysis of 16 B-ALL samples. In 12 cases (black columns), ZAP-70 protein values were high. C, correlation between QRT-PCR and flow cytometry analysis of ZAP-70 expression in B-ALLs and CLLs samples. There was a logarithmic correlation between both methods (R2 = 0.7; P < 0.0001; see also A and B).

Expression of ZAP-70 was also analyzed by QRT-PCR in 20 B-ALLs cases. To rule out the influence of contaminating T cells in non–CD19+-purified cases, two different strategies were done: ZAP-70 expression analysis in serial dilutions of T cells and a ZAP-70 nonexpressing cell line (Jurkat and JVM-2), and comparison of the values obtained before and after B-cell purification in eight B-ALL cases. Using these approaches, we found that the presence of <10% of T cells did not significantly influence the values of ZAP-70 expression (data not shown). Consequently, when CD19+ purification was not possible, only the B-ALL cases with a total number of T and natural killer cells <10% were included in the analysis.

Normal B cells and ZAP-70 nonexpressing cell lines exhibited a mean relative expression of 0.042 AU (SD, ±0.052 AU). Therefore, values of QRT-PCR above 0.20 AU (average ± 3 SDs) were considered as having high relative levels of ZAP-70 expression. With this cutoff, 9 of 20 B-ALLs showed high levels of ZAP-70 expression (range, 0.34-0.81 AU), whereas in the remaining cases, these levels were similar to normal B cells (range, 0.01-0.19 AU; Table 1; Fig. 5). Of note, in 7 B-ALL cases and in 10 CLL cases in which ZAP-70 expression was analyzed by QRT-PCR and flow cytometry, there was a logarithmic correlation between both methods (R2 = 0.7; P < 0.0001; Fig. 5).

Overall, we found a high expression of ZAP-70 in 13 of 23 (56%) B-ALLs with pro/pre B phenotype. Moreover, four of six Burkitt/ALL disclosed increased expression of ZAP-70. The levels of ZAP-70 in these Burkitt/ALL cases were found in the higher range of the series.

ZAP-70 expression and clinicobiological variables in B-ALLs. No relationship was observed between ZAP-70 expression levels and the maturation status of the B-ALLs or the detected genetic abnormalities, including the presence of bcr/abl rearrangement (Table 1). Of note, all the cases with high ZAP-70 expression showed increased expression of CD38, whereas the three cases with low CD38 disclosed low levels of ZAP-70 (Fisher's exact test, P = 0.05).

Twenty patients diagnosed with B-ALL were evaluable for prognosis. Cases with a lymphoid blast crisis of a chronic myelogenous leukemia, Burkitt's lymphoma, or without enough clinical data were not included in the analysis. There was no correlation between ZAP-70 expression and response to the induction treatment (data not shown). As per the duration of response and survival, the series was too heterogeneous to perform a meaningful analysis, because the great majority of patients diagnosed with B-ALL bcr/abl+ underwent allogeneic transplant, for this reason being not comparable with the rest of the patients from this series.

Mutational analysis of ZAP-70 in B-ALLs. Different point mutations in the exons 3, 12, and 13 of the ZAP-70 gene have been shown to cause deficient ZAP-70 protein expression in human T cells, leading to absence of peripheral CD8+ T cells and/or different forms of severe combined immunodeficiency (2, 3, 17–19). To rule out the presence of mutations in the coding portion of the ZAP-70 gene in B-ALLs not expressing ZAP-70, sequencing of the 5′-untranslated region, coding, and adjoining intronic regions was done, and the sequences were compared with the wild-type sequence (Genbank accession no. L05148.1). The mutational analysis did not reveal the presence of mutations, deletions, or insertions in B-ALL cases with low ZAP-70 expression. Three polymorphisms already described (see http://www.idibaps.ub.edu/images/noticias/ZAP70SEQ.pdf) were found in both ZAP-70 expressing and nonexpressing B-ALLs.

ZAP-70 phosphorylation and pre-TCR/TCR pathway in B-ALL cases. To determine whether ZAP-70 protein was phosphorylated in B-ALL cells, Western blot analysis was done using an anti–phospho-ZAP-70/phospho-Syk antibody that detects a phosphorylated-active ZAP-70 protein (P-ZAP-70) at the Tyr319 residue, and the orthologous Tyr352 residue in Syk (P-Syk). These residues are required for the assembly of a signaling complex that leads to the activation of the PLCγ1-dependent and Ras-dependent signaling cascades (20, 21). Syk protein is the other member of the Syk/ZAP-70 family normally expressed in cells of B-cell lineage that is required for the pre-BCR/BCR signaling (22–24). To rule out an alternate expression between Syk and ZAP-70 in B-ALL, the expression and the phosphorylation status of Syk protein was also analyzed in B-ALL cells. Western blot of total cell lysates revealed that Syk was expressed in all the samples analyzed, including cases with low ZAP-70 expression (data not shown). In untreated B-ALL cells, Western blot analysis revealed that neither ZAP-70 nor Syk were constitutively activated. Treatment of these cells with pervadanate, a broad phosphatase inhibitor (25), significantly increased the intensity of ZAP-70 and Syk phosphorylation (Fig. 6). Interestingly, Lck protein, a Src-kinase required for ZAP-70 kinase phosphorylation activity (4, 26, 27), was detected in all B-ALL cases (Fig. 6).

Fig. 6.
Fig. 6.

Western blot analysis of the expression of proteins involved in pre-BCR signaling in B-ALL cells. Two representative B-ALL cases that expressed ZAP-70 (ALL-1 and ALL-4) were analyzed. The Jurkat cell line was used as positive control for ZAP-70 expression. Cells were treated with pervanadate (PV), a broad phosphatase inhibitor, to analyze the phosphorylation status of different proteins analyzed. Expression of α-tubulin was determined as a control of protein load. Expression of P-ZAP-70, P-Syk, ZAP-70, P-LAT, LAT, and Lck in B-ALL cells was analyzed using direct antibodies. ZAP-70 protein was found to be significantly phosphorylated at Tyr319 and Syk in Tyr352 in B-ALL cells. Moreover, LAT was phosphorylated at Tyr226 upon treatment with pervanadate. The Src-kinase Lck, required for ZAP-70 signaling, was expressed in all the cases analyzed. Analysis of phosphotyrosines (P-tyr's) in the high molecular weigh area of each blot was done to control pervanadate treatment.

Different signaling elements belonging to the pre-TCR/TCR signal pathway have been described in human and mice pro/pre B cells and B-ALL cells (28–30). One of these elements is the linker for activation of T cells (LAT) protein (27–29, 31–33), a transmembrane adapter molecule expressed in T cells but not in normal mature B cells. In CD19+-purified B-ALL cells, we found that LAT was expressed in all the cases, confirming the results previously reported in normal pro/pre B cells (28, 29). Tyr226 residue of LAT becomes phosphorylated in T cells following TCR engagement (32, 34, 35). Using an anti-P-LAT antibody, this residue proved to be phosphorylated upon pervanadate stimulation (Fig. 6). These results showed the presence of other pre-TCR/TCR signaling elements in B-ALLs apart from ZAP-70.

Discussion

ZAP-70, a tyrosine kinase of the Syk/ZAP-70 family that plays a critical role in the signal transduction from the TCR, has been reported to be expressed in T and natural killer derived cells (1–3). Recently, ZAP-70 expression has been shown to be expressed in mice pro/pre B cells, its presence being important for B-cell development (11). Surprisingly, ZAP-70 expression has also been found in a mature B-cell–derived neoplasm as CLL (6), particularly in cases with unmutated IgVH genes (7–9), where it seems to contribute to enhancing the signal from the BCR (10). These results pose the question whether ZAP-70 expression in CLL is an aberrant phenomenon related to the neoplasm or is a reflection of a normal B-cell counterpart of CLL expressing ZAP-70. The abovementioned results prompted us to analyze ZAP-70 expression in different human B-cell subsets and B-ALLs. Among normal B cells, ZAP-70 was only found expressed in CD34+ or CD10+ B cells, whereas no expression was observed in mature B-cell subsets from bone marrow, tonsil, and peripheral blood. Moreover, the expression of ZAP-70 protein found in CD34+ or CD10+ B cells obtained by flow cytometry and Western blot was inferior to that in T cells, in accordance to the results found in mice pro/pre B cells (11). Although expected, ZAP-70 expression in human pro/pre B cells has not been previously reported. Thus, recent gene expression profile done on pro/pre B cells did not clarify whether ZAP-70 was expressed (30).

Our results reasonably rule out the possibility of the existence of a significant proportion of mature B cells expressing ZAP-70. In this sense, expression of ZAP-70 in normal mature B cells has not been reported because this gene was cloned and found to be expressed only in cell lines of T or natural killer lineage (1). Thus, we and others showed that ZAP-70 is expressed in pro/pre B cells from mice and human but not in mature B cells. The expression found in mice splenic cells was attributed to mature B cells, but these cells were not phenotypically characterized and would correspond to immature B cells transiting to the spleen. In addition to that, we previously found the lack of ZAP-70 expression in normal CD5+ or CD5− B cells from peripheral blood (7). Furthermore, in a recently published report (36), it was found ZAP-70 expression in a very low percentage of mature B cells from different tissues. Although an overinterpretation of ZAP-70 intensity and/or T-cell contamination could not be completely excluded in that article, it is also possible that in our report, even with the use of several and sensitive methods, a small percentage of B cells expressing ZAP-70 was not detected, as we observed a <0.1% B cells expressing ZAP-70 in tonsil.

ZAP-70 expression was found in 56% of B-ALL cases analyzed with pro/pre B phenotype. This is probably a consequence of the cell of origin of these neoplasms, as we found ZAP-70 expressed in normal pro/pre B cells. ZAP-70 expression was also analyzed in a small series of patients recently analyzed (37). In this report, a expression of ZAP-70 was found in all the cases analyzed, opposite to our results and to those recently published, in which ZAP-70 expression was analyzed by oligonucleotide arrays (38). In the later report, it was found an important correlation between ZAP-70 expression and the relapse rate (38). This analysis, however, was done in a series of cases without relevant genetic abnormalities (38). The series of patients herein reported was too heterogeneous in terms of genetic abnormalities and given therapy to analyze the clinical effect of ZAP-70 expression.

There is no clear explanation for the lack of ZAP-70 expression, found at both mRNA and protein levels, in some cases of pro/pre B-ALLs. In this sense, we did not observe mutations in the coding or 5′-untranslated region regions of the gene, as has been described in severe combined immunodeficiencies (2, 3, 17–19). In this sense, the lack of expression of ZAP-70 found in some B-ALL cases could be related to other pre-BCR signaling defects also described in this leukemia, similar to the lack of expression of SLP-65 or Syk reported in some B-ALL cases (39, 40).

Expression of other components of the pre-TCR/TCR signaling cascade, like LAT and SLP-76, has been found in mice and human pro/pre B cells. These proteins are probably acting as functionally redundant signaling molecules to the pre-BCR components (28, 29) to ensure maximum efficiency of its signal transduction. In our study, in B-ALLs ZAP-70 and Syk were found phosphorylated at the Tyr319 residue and at the Tyr352 residue, respectively. In addition, LAT, P-LAT, and the Src-kinase Lck were also found in all the B-ALL cases analyzed. These findings point out that ZAP-70, when expressed, is functionally active in B-ALL cells. In this setting, our finding of pre-TCR/TCR signaling elements in pro/pre B-ALL cells is in agreement with the hypothesis of the usage of pre-TCR/TCR signaling elements by the pre-BCR (28).

Interestingly, ZAP-70 expression was observed in Burkitt/ALL cases with the t(8;14)(q24;q32) at the highest levels observed among B-ALLs and CLLs (7). In accordance to this, we and others recently described ZAP-70 expression in a variable percentage of Burkitt's lymphomas (41–43), suggesting that this gene could play a role in the pathogenesis of this disease. The expression of ZAP-70 found in Burkitt and in 50% of CLL cases (7) suggests that this gene is aberrantly expressed in mature B-cell–derived neoplasms, as we did not observe ZAP-70 expression in normal mature B cells. Increased expression of ZAP-70 in a mature neoplasm like CLL correlates with an adverse behavior of the disease (7). Further investigations are warranted to determine whether ZAP-70 expression in Burkitt's lymphoma is associated with particular clinical and biological features.

In conclusion, this study shows that ZAP-70 was expressed in normal human pro/pre B cells but not in normal mature B cells. ZAP-70 expression was also found in one half of the B-ALLs analyzed, probably reflecting the lineage origin of such cases. In addition, other elements of the pre-TCR/TCR signaling cascade were found to be both expressed and phosphorylated in B-ALLs. Finally, the absence of ZAP-70 in normal mature B cells suggests that the expression observed in mature B-cell–derived neoplasms with different cellular origin, such as Burkitt/ALL and CLL reflects an aberrant phenomenon. Further investigations focused on the mechanisms regulating ZAP-70 expression in mature B-cell neoplasms are warranted.

Acknowledgments

We thank Drs. Assumpcio Cuchi (Department of Otorhinolaryngology, Hospital Clinic, Barcelona, Spain), Pablo Engel (Department of Cellular Biology and Pathology, Universitat de Barcelona, Barcelona, Spain), and J. Sabin (Department of Otorhinolaryngology, Hospital Sant Joan de Déu, Barcelona, Spain) for providing us with the tonsil samples, Dr. Riccardo Dalla-Favera for the critical review of the article, and Eoin McGrath for his assistance in the preparation of the article.

Footnotes

  • Grant support: Fondo de Investigaciones Sanitarias grant 02/0250, Deutsche José Carreras Leukämie-Stiftung e.V. grant D-1643, and the José Carreras International Foundation Against Leukemia grant EM/03.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Note: Supplementary data for this article are available at http://www.idibaps.ub.edu/images/noticias/ZAP70SEQ.pdf. M. Crespo and N. Villamor contributed equally to this study.

    • Accepted November 18, 2005.
    • Received July 14, 2005.
    • Revision received November 11, 2005.

References

  1. ↵
    Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71:649–62.
    OpenUrlCrossRefPubMed
  2. ↵
    Arpaia E, Shahar M, Dadi H, Cohen A, Roifman CM. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 1994;76:947–58.
    OpenUrlCrossRefPubMed
  3. ↵
    Chan AC, Kadlecek TA, Elder ME, et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 1994;264:1599–601.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Ashe JM, Wiest DL, Abe R, Singer A. ZAP-70 protein promotes tyrosine phosphorylation of T cell receptor signaling motifs (ITAMs) in immature CD4(+)8(+) thymocytes with limiting p56(lck). J Exp Med 1999;189:1163–8.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kong G, Dalton M, Wardenburg JB, Straus D, Kurosaki T, Chan AC. Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function. Mol Cell Biol 1996;16:5026–35.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052–7.
    OpenUrlCrossRefPubMed
  7. ↵
    Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–75.
    OpenUrlCrossRefPubMed
  8. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–51.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–11.
    OpenUrlCrossRefPubMed
  10. ↵
    Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609–14.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz VL. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003;18:523–33.
    OpenUrlCrossRefPubMed
  12. ↵
    van Dongen JJ. Proposals for immunological classification of acute leukemias. Leukemia 1995;9:2149–50.
    OpenUrlPubMed
  13. ↵
    Marafioti T, Jones M, Facchetti F, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003;102:2868–76.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Mason DY, Micklem K, Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 2000;191:452–61.
    OpenUrlCrossRefPubMed
  15. ↵
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
    OpenUrlFREE Full Text
  16. ↵
    Tatusova TA, Madden TL. “Blast 2 sequences: a new tool for comparing protein and nucleotide sequences”. FEMS Microbiol Lett 1999;174:247–50.
    OpenUrlCrossRefPubMed
  17. ↵
    Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994;264:1596–9.
    OpenUrlAbstract/FREE Full Text
  18. Toyabe S, Watanabe A, Harada W, Karasawa T, Uchiyama M. Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology 2001;103:164–71.
    OpenUrlCrossRefPubMed
  19. ↵
    Elder ME, Skoda-Smith S, Kadlecek TA, Wang F, Wu J, Weiss A. Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 2001;166:656–61.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Williams BL, Irvin BJ, Sutor SL, et al. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation. EMBO J 1999;18:1832–44.
    OpenUrlAbstract
  21. ↵
    Law CL, Chandran KA, Sidorenko SP, Clark EA. Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol Cell Biol 1996;16:1305–15.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303–6.
    OpenUrlCrossRefPubMed
  23. Kurosaki T. Molecular mechanisms in B cell antigen receptor signaling. Curr Opin Immunol 1997;9:309–18.
    OpenUrlCrossRefPubMed
  24. ↵
    Zhang J, Berenstein E, Siraganian RP. Phosphorylation of Tyr342 in the linker region of Syk is critical for Fc epsilon RI signaling in mast cells. Mol Cell Biol 2002;22:8144–54.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Secrist JP, Burns LA, Karnitz L, Koretzky GA, Abraham RT. Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J Biol Chem 1993;268:5886–93.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001;13:299–306.
    OpenUrlCrossRefPubMed
  27. ↵
    Kolanus W, Romeo C, Seed B. T cell activation by clustered tyrosine kinases. Cell 1993;74:171–83.
    OpenUrlCrossRefPubMed
  28. ↵
    Su YW, Jumaa H. LAT links the pre-BCR to calcium signaling. Immunity 2003;19:295–305.
    OpenUrlCrossRefPubMed
  29. ↵
    Oya K, Wang J, Watanabe Y, Koga R, Watanabe T. Appearance of the LAT protein at an early stage of B-cell development and its possible role. Immunology 2003;109:351–9.
    OpenUrlCrossRefPubMed
  30. ↵
    Terskikh AV, Miyamoto T, Chang C, Diatchenko L, Weissman IL. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 2003;102:94–101.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Finco TS, Kadlecek T, Zhang W, Samelson LE, Weiss A. LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity 1998;9:617–26.
    OpenUrlCrossRefPubMed
  32. ↵
    Lin J, Weiss A. Identification of the minimal tyrosine residues required for linker for activation of T cell function. J Biol Chem 2001;276:29588–95.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998;92:83–92.
    OpenUrlCrossRefPubMed
  34. ↵
    Zhang W, Trible RP, Zhu M, Liu SK, McGlade CJ, Samelson LE. Association of Grb2, Gads, and phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell antigen receptor-mediated signaling. J Biol Chem 2000;275:23355–61.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Paz PE, Wang S, Clarke H, Lu X, Stokoe D, Abo A. Mapping the Zap-70 phosphorylation sites on LAT (linker for activation of T cells) required for recruitment and activation of signalling proteins in T cells. Biochem J 2001;356:461–71.
    OpenUrlCrossRefPubMed
  36. ↵
    Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005;19:1018–24.
    OpenUrlCrossRefPubMed
  37. ↵
    Guillaume N, Alleaume C, Munfus D, et al. ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica 2005;90:899–905.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Chiaretti S, Guarini A, De Propris MS, et al. ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 re-arrangement and the pre-B stage of differentiation, and prognostic implications. Blood 2005;107:197–204.
    OpenUrlPubMed
  39. ↵
    Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 2001;20:3969–78.
    OpenUrlCrossRefPubMed
  40. ↵
    Jumaa H, Bossaller L, Portugal K, et al. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 2003;423:452–6.
    OpenUrlCrossRefPubMed
  41. ↵
    Admirand JH, Rassidakis GZ, Abruzzo LV, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004;17:954–61.
    OpenUrlCrossRefPubMed
  42. Sup SJ, Domiati-Saad R, Kelley TW, Steinle R, Zhao X, Hsi ED. ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol 2004;122:582–7.
    OpenUrlCrossRefPubMed
  43. ↵
    Carreras J, Villamor N, Colomo L, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205:507–13.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Clinical Cancer Research: 12 (3)
February 2006
Volume 12, Issue 3

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia
Marta Crespo, Neus Villamor, Eva Giné, Ana Muntañola, Dolors Colomer, Teresa Marafioti, Margaret Jones, Mireia Camós, Elias Campo, Emili Montserrat and Francesc Bosch
Clin Cancer Res February 1 2006 (12) (3) 726-734; DOI: 10.1158/1078-0432.CCR-05-1531
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement